Side-by-side comparison of AI visibility scores, market position, and capabilities
Allentown PA industrial gases and clean hydrogen (NYSE: APD) $12.1B FY2024 revenue; NEOM green hydrogen $8.5B megaproject, CEO transition Oct 2024, Mantle Ridge activism competing with Linde and Air Liquide.
Air Products and Chemicals, Inc. is an Allentown, Pennsylvania-based industrial gases and energy transition company — publicly traded on the New York Stock Exchange (NYSE: APD) as an S&P 500 Materials component — producing and distributing atmospheric gases (oxygen, nitrogen, argon), process gases (hydrogen, helium, carbon dioxide), and specialty gases for industrial, healthcare, and clean energy applications through approximately 22,000 employees in 50+ countries. In fiscal year 2024 (ending September 2024), Air Products reported revenues of $12.1 billion with adjusted EBITDA of approximately $3.9 billion, as the company continued executing its massive green hydrogen mega-project portfolio despite significant capital deployment raising Net Debt-to-EBITDA above 4x. In October 2024, longtime CEO Seifi Ghasemi retired after a decade leading Air Products' transformation from a traditional industrial gases company to a clean hydrogen investment vehicle — Eduardo Menezes was appointed CEO, with activist investor Mantle Ridge (holding approximately 10% of Air Products shares) advocating for strategic refocus, capital discipline, and potential strategic alternatives to the green hydrogen mega-project strategy. Air Products' industrial gases business (oxygen for steel production, nitrogen for food preservation and semiconductor manufacturing, hydrogen for petroleum refining) generates $8+ billion in recurring revenues from long-term take-or-pay contracts with petrochemical, steel, and healthcare customers — providing the cash flow foundation that supports green hydrogen capital investment.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.